SynthesisEndocrine2026
Benign androgen-producing adrenal tumors: A systematic review of cases and case series.
Synthesis in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo characterize the clinical, biochemical, radiological, and histological features of benign androgen-producing adrenal tumors in adults.
methodsSystematic review of published case reports and case series. A systematic search of PubMed, Web of Science, and Scopus was conducted for studies published between 1980 and 2024. Eligible cases included adults (≥ 19 years) with histologically confirmed benign adrenal tumors, biochemical evidence of androgen excess with postoperative normalization, and available individual patient data. Extracted variables included demographics, clinical signs, hormonal values, imaging, and histopathology.
resultsNinety-seven cases from 81 publications fulfilled inclusion criteria. Most were women (96/97), with a mean age of 42.1 years. Hirsutism (87.5%) and clitoromegaly (55.2%) were the most common features, though a minority of tumors were discovered incidentally, often in postmenopausal women. While most tumors were unilateral adenomas, 18% showed alternative histologies, including oncocytomas and ganglioneuromas. Total testosterone was elevated in 93.4% of women, DHEAS in 69.4%; combined assessment achieved 100% sensitivity. However, 25.9% of cases did not exceed thresholds commonly used to suggest tumoral hyperandrogenism (7 nmol/L for testosterone, 18.5 µmol/L for DHEAS), highlighting a risk of underdiagnosis. A paradoxical androgen rise after dexamethasone was observed in ~ 30% of tested cases. Cortisol co-secretion was present in 28% of cases.
conclusionBenign androgen-producing adrenal tumors are rare but clinically significant. They predominantly affect women and may present with subtle or atypical findings, or be discovered incidentally. Reliance on strict hormonal cut-offs may overlook some cases. Broader biochemical assessment and clinical suspicion are crucial to ensure accurate diagnosis.
Indexed as
Identifiers
41563634What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.